JUN 23, 2015 04:37 PM PDT

Catching Cancer Faster

A non-invasive breath test designed in the United Kingdom could save 10,000 lives per year by diagnosing the early signs of esophageal and gastric cancer in minutes. Researchers claim that the test is 90 percent accurate, as well as being "cheaper, faster and easier to perform than other methods." According to an article in Science Daily, excerpted from materials written by Maxine Myers at Imperial College London, the device could also save the British health care system 145 million pounds per year (http://www.sciencedaily.com/releases/2015/06/150623072902.htm).
Breath analysis can detect cancer at early stages, according to British researchers.
In a clinical study involving three London hospitals, researchers analyzed breath samples from 210 patients and found that the test could distinguish between malignant and benign esophageal cancer with 90-percent accuracy in minutes. The test consists of having the patients breathe into a device similar to a breathalyzer that is connected to a bag. The compounds from the patients' breath are analyzed by a selected ion flow tube mass spectrometer.

Chemical compounds in exhaled breath provide evidence of esophageal and gastric cancer, according to the researchers. These volatile organic compounds (VOC) produce a distinctive smell to help detect early signs of the disease. The selected ion flow tube mass spectrometer, an analytical instrument, identifies VOCs present at significantly higher concentrations in patients with esophageal and gastric cancer than in non-cancerous patients. Results could establish a biomarker, a biological feature used to measure the presence or progress of a disease, according to the researchers.

According to Professor George Hanna, lead author of the study and director of NIHR-Diagnostic Evidence Cooperatives at Imperial College London, "Esophageal and gastric cancers are on the rise in the UK with more than 16,000 new cases diagnosed each year. The current method for detecting these cancers is expensive, invasive and a diagnosis is usually made at a late stage, and often the cancer has spread to other parts of the body. This makes it harder to treat and results in poor long-term survival rates. Our breath test could address these problems, because it can help diagnose patients with early non-specific symptoms as well as reduce the number of invasive endoscopies carried out on patients, which often lead to negative results. Diagnosis at an early stage could give patients more treatment options and ultimately save more lives."

Another breakthrough breath analyzer device can identify lung and bowel cancer before any symptoms develop, giving patients a chance to be treated sooner and increasing their chances of survival. The system uses a coin-sized nanochip to analyze a patient's breath for tiny traces of chemicals produced by the disease. The LuCID device - lung cancer indicator detection - will be assessed in two NHS hospitals this summer in a £1million clinical trial. Billy Boyle of the Cambridge University spin-off firm Owlstone Nanotech, which developed the device, described it as being "like a sniffer dog on a mobile phone," according to an article in the London Daily Mirror (http://www.mirror.co.uk/lifestyle/health/cancer-breath-test-could-save-5135643).
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
AUG 07, 2018
Cancer
AUG 07, 2018
Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
DNA methylation patterns in renal cell carcinoma (RCC) have a strong association with myelodysplastic syndrome DNA hypermethylation later in life....
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 31, 2018
Cancer
OCT 31, 2018
Researchers identify a protein marker that induces dormancy in metastatic breast cancer
Researchers at the Mount Sinai hospital identified for the first time a protein marker that could indicate whether breast cancer will further metastasize or remains in a dormant state accordi...
NOV 05, 2018
Videos
NOV 05, 2018
How UV Rays Cause Aging and Skin Cancer
We know that UV rays can do damage to our DNA - but how?...
DEC 04, 2018
Immunology
DEC 04, 2018
Why is Skin Cancer so Elusive?
A pathway involved in skin cancer reveals a potential immunotherapy target...
Loading Comments...